---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-018894"
form_type: "8-K"
ticker: "DARE"
cik: "0001401914"
company_name: "Dare Bioscience, Inc."
filed_at: "2025-07-14T23:59:59+00:00"
generated_at: "2026-05-18T06:37:42.457274+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Daré's Ovaprene Phase 3 interim shows ~9% pregnancy rate; DSMB OK to continue

## Summary
- DSMB recommended study continue without modification after planned interim safety analysis.
- ~9% of treated women had experienced a pregnancy, consistent with company expectations.
- ~17% discontinued due to vaginal odor; no serious safety concerns or new tolerability issues.
- ~115 of target ~250 participants ongoing/completed; final primary endpoint uses Pearl Index.
- Bayer can obtain U.S. commercialization rights with $20M payment, plus up to $310M milestones and tiered royalties.

## SEC filing metadata
- accession: 0001641172-25-018894
- form_type: 8-K
- ticker: DARE
- cik: 0001401914
- company_name: Dare Bioscience, Inc.
- filed_at: 2025-07-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1401914/000164117225018894/0001641172-25-018894-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1401914/000164117225018894/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-018894
- JSON: https://secwatch.observer/filing/0001641172-25-018894.json
- Plain text: https://secwatch.observer/filing/0001641172-25-018894.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.